LONG TRACKING ANALYSIS ABOUT MANAGEMENT OF AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME

被引：0
|
作者：
Molero, A. [1 ]
Mora, E. [2 ,3 ]
Avila, F. [4 ]
Revelles, M. [5 ]
Merchan, B. [1 ]
Regadera, A. [2 ,3 ]
Alonso, S. [4 ]
Montoro, J. [1 ]
Martin, M. [2 ,3 ]
Benlloch, L. [6 ]
Garcia, R. [5 ]
Bernal, T. [4 ]
Sanz, G. [2 ,3 ]
Valcarcel, D. [1 ]
机构：
[1] Hosp Univ Vall dHebron, Hematol, Barcelona, Spain
[2] Hosp Univ La Fe, Hematol, Valencia, Spain
[3] Politecn La Fe, Hematol, Valencia, Spain
[4] Hosp Univ Cent Asturias Oviedo, Hematol, Oviedo, Spain
[5] Hosp Univ Virgen de la Victoria, Hematol, Malaga, Spain
[6] Spanish MDS Grp, Valencia, Spain
来源：
LEUKEMIA RESEARCH | 2017年 / 55卷
关键词：
D O I：
10.1016/S0145-2126(17)30219-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
106
引用
收藏
页码：S66 / S66
页数：1
相关论文
共 50 条
  • [11] Necrotizing fasciitis in two patients with myelodysplastic syndrome treated with azacitidine
    Lai, Shiue-Wei
    Huang, Tzu-Chuan
    Ye, Ren-Hua
    Wu, Yi-Ying
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 94 (03) : 273 - 276
  • [12] Karyotype does not predict response to azacitidine in patients with myelodysplastic syndrome
    Juvvadi, R.
    Rossetti, J. M.
    Shadduck, R. K.
    Kaplan, R. B.
    Kennedy, M.
    Falke, E.
    Kramer, W.
    Lister, J.
    LEUKEMIA RESEARCH, 2007, 31 : S122 - S123
  • [13] Impact of cytogenetic abnormalities on response to azacitidine in patients with myelodysplastic syndrome
    Iizuka, Hiroko
    Sugimoto, Keiji
    Takizawa, Haruko
    Wakabayashi, Mutsumi
    Sakajiri, Sakura
    Sekiguchi, Yasunobu
    Noguchi, Masaaki
    Komatsu, Norio
    ANNALS OF ONCOLOGY, 2019, 30
  • [14] Response to azacitidine (AZA) in patients with secondary myelodysplastic syndrome.
    Abdulhaq, H.
    Haq, B.
    Rossetti, J.
    Lister, J.
    Shadduck, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 356S - 356S
  • [15] Treatment of Myelodysplastic syndrome with azacitidine and erythropoietin
    Limaye, Sewanti
    Lipshitz, Jay
    Dulala, Renuka
    Patel, Dilip
    BLOOD, 2007, 110 (11) : 230B - 230B
  • [16] Genome-Wide DNA Methylation Analysis of Patients with Myelodysplastic Syndrome After Azacitidine Treatment
    Byun, Hyang-Min
    Triche, Timothy, Jr.
    Kim, Hyeoung-Joon
    Kim, Hee Nam
    Kim, Yeo-Kyeoung
    Lee, Il-Kwon
    Ahn, Jae-Sook
    Lee, Je-Jung
    Yang, Deok-Hwan
    Kook, Hoon
    Hwang, Tai Ju
    Laird, Peter W.
    Weisenberger, Daniel
    Yang, Allen S.
    BLOOD, 2009, 114 (22) : 249 - 249
  • [17] THERAPY-RELATED MYELODYSPLASTIC SYNDROME: AN ANALYSIS OF 5 RISK MODELS IN PATIENTS TREATED WITH AZACITIDINE
    Duong, V.
    Lancet, J.
    Al-Ali, N.
    List, A.
    Komrokji, R.
    HAEMATOLOGICA, 2012, 97 : 368 - 369
  • [18] Experience with the use of azacitidine in patients with low-risk myelodysplastic syndrome
    Duarte, F.
    Santos, T.
    Barbosa, M.
    Santos, T.
    Goncalves, R.
    LEUKEMIA RESEARCH, 2013, 37 : S166 - S166
  • [19] Impact of Skeletal Muscle Depletion on Patients with Myelodysplastic Syndrome Treated with Azacitidine
    Takada, Eri
    Nakamura, Nobuhiko
    Kaneda, Yuto
    Fukuno, Kenji
    Lee, Shin
    Fujita, Kei
    Morishita, Tetsuji
    Ikoma, Yoshikazu
    Matsumoto, Takuro
    Nakamura, Hiroshi
    Kitagawa, Junichi
    Kanemura, Nobuhiro
    Kasahara, Senji
    Hara, Takeshi
    Tsurumi, Hisashi
    Shimizu, Masahito
    HEMATOLOGY REPORTS, 2024, 16 (01) : 114 - 124
  • [20] A Phase I Study of Vosaroxin Plus Azacitidine for Patients with Myelodysplastic Syndrome
    Jacoby, Meagan A.
    Abboud, Camille N.
    Dipersio, John F.
    Cashen, Amanda F.
    Walter, Matthew J.
    Pizarro, Rigoberto De Jesus
    Uy, Geoffrey L.
    BLOOD, 2015, 126 (23)
12345